ConMed(CNMD.US) Director Buys US$141.96K in Common Stock
$ConMed(CNMD.US)$ Director Aronson Martha Goldberg purchased 2,000 shares of common stock on May 6, 2024 at an average price of $70.98 for a total value of $141.96K.Source: Announcement What is statem
An Intrinsic Calculation For CONMED Corporation (NYSE:CNMD) Suggests It's 50% Undervalued
Key Insights CONMED's estimated fair value is US$141 based on 2 Stage Free Cash Flow to Equity CONMED's US$70.75 share price signals that it might be 50% undervalued Analyst price target for CNMD
Needham: Reiterates the Conmed (CNMD.US) rating and adjusted from buy to buy rating, target price is $107.00.
Needham: Reiterates the Conmed (CNMD.US) rating and adjusted from buy to buy rating, target price is $107.00.
Needham Reiterates Buy on Conmed, Maintains $107 Price Target
Needham analyst Mike Matson reiterates Conmed (NYSE:CNMD) with a Buy and maintains $107 price target.
Conmed's Resilience Justifies Buy Rating Amid New Market Challenges
$1M Bet On Skyworks Solutions? Check Out These 3 Stocks Insiders Are Buying
Although U.S. stocks closed higher on Thursday, there were a few notable insider trades.When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the st
Insider Buying Alert: COO Pat Beyer Acquires Shares of Conmed Corp (CNMD)
ConMed(CNMD.US) Officer Buys US$204.9K in Common Stock
$ConMed(CNMD.US)$ Officer Beyer Pat purchased 3,000 shares of common stock on Apr 30, 2024 at an average price of $68.3 for a total value of $204.9K.Source: Announcement What is statement of changes i
CONMED Corporation to Present at the BofA Securities Healthcare Conference
LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced that Curt R. Hartman, Chair of the Board, President, and Chief Executive Officer, Todd W. Garner, Executive Vice President
Analysts Offer Insights on Healthcare Companies: Thermo Fisher (TMO), Conmed (CNMD) and BioMarin Pharmaceutical (BMRN)
Piper Sandler Sticks to Their Buy Rating for Conmed (CNMD)
CONMED Corporation (NYSE:CNMD) Q1 2024 Earnings Call Transcript
CONMED First Quarter 2024 Earnings: Beats Expectations
Conmed Is Maintained at Overweight by JP Morgan
Conmed Is Maintained at Overweight by JP Morgan
Komo: Maintaining the Conmed (CNMD.US) rating, adjusted from an increase in holdings to an increase rating, and the target price was adjusted from $115.00 to $75.00.
Komo: Maintaining the Conmed (CNMD.US) rating, adjusted from an increase in holdings to an increase rating, and the target price was adjusted from $115.00 to $75.00.
JP Morgan Maintains Overweight on Conmed, Lowers Price Target to $75
JP Morgan analyst Robbie Marcus maintains Conmed (NYSE:CNMD) with a Overweight and lowers the price target from $115 to $75.
CONMED (CNMD) Q1 Earnings & Revenues Surpass Estimates
CONMED Shares Are Trading Lower After the Company Reported Q1 Financial Results. Needham, Piper Sandler and Wells Fargo Lowered Their Respective Price Targets on the Stock.
CONMED Shares Are Trading Lower After the Company Reported Q1 Financial Results. Needham, Piper Sandler and Wells Fargo Lowered Their Respective Price Targets on the Stock.
Wells Fargo Adjusts Price Target on CONMED to $77 From $98, Maintains Equalweight Rating
CONMED (CNMD) has an average outperform rating and price target range of $75 to $132, according to analysts polled by Capital IQ. Price: 63.92, Change: -6.09, Percent Change: -8.70
Conmed Appoints New Chief Operating Officer
No Data